When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
HALO - Halozyme reports positive results from Perjeta + Herceptin combination study
Halozyme Therapeutics Inc.
Halozyme Therapeutics (NASDAQ:HALO) announces that the global phase III FeDeriCa study conducted by Genentech, met its primary endpoint. The study investigated a fixed-dose combination of pertuzumab (Perjeta) and trastuzumab (Herceptin) for subcutaneous administration using Halozyme's ENHANZE drug delivery technology in combination with intravenous chemotherapy.
More news on: Halozyme Therapeutics, Inc., Healthcare stocks news,